-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
On March 30th, Tianjing Bio and South Korea’s ABL Bio jointly announced that the bispecific antibody TJ-CD4B (also known as ABL111) that targets Claudin 18.
TJ-CD4B is an innovative bispecific antibody that simultaneously targets the tumor antigen claudin 18 splice 2 (Claudin 18.
Preclinical studies have shown that even in the case of low expression of Claudin 18.
This time, approved in the United States is a multi-center Phase 1 dose-climbing trial, which will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ-CD4B in patients with advanced or metastatic solid tumors.